Ataxia – Pipeline Review, 2019

Ataxia is characterized as a degenerative disease of the nervous system. People suffering from ataxia generally experience dysarthria, abnormalities while walking or uncoordinated use of their arms or hands. There are different types of ataxia such as Friedreich’s ataxia, Ataxia –telangiectasia, spinocerebellar ataxias, and episodic ataxia. According to the National Institute of Neurological Disorders (NINDS), Friedreich ataxia is considered as the most common type of hereditary ataxia that usually affects at least 1 in 50,000 populations globally every year.

Currently, there are no specific treatments or cure available for the treatment of ataxia. Generally, various therapies such as speech & language therapy, occupation therapy, and physiotherapy and medications are used to treat the symptoms associated with ataxia. Episodic ataxia is controlled using acetazolamide. Antibiotics or antiviral medications are sometimes used to treat acquired ataxia and sometimes vitamin E supplements are used to treat ataxia for patients with vitamin E deficiency. 

Pharmaceutical companies along with various research institutes have been focusing on studying and developing new treatment options for ataxia. For instance; MIN-102, which is being studied by Minoryx Therapeutics, S.L., is currently in phase-2 clinical trials for the study of Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female Patients

To know how our report can help streamline your business, Speak to Analyst

At present around 72% of the pipeline candidates for Ataxia are in the phase-1 and phase-2 stage. More than half of the studies are sponsored by government research organizations and many are sponsored by industries.

Report Description

The report on ‘Ataxia – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Ataxia. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Ataxia.

The report on ‘Ataxia – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Acromegaly
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Acromegaly
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary